Dr. Theodore W. Laetsch JR., MD
Pediatrics (Pediatrics Physician)
At a glance
- In the NPI registry since
- 2007
Licensed in Texas since 2013, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatrics Physician primary
PA license MD436327 -
Pediatric Hematology & Oncology Physician
PA license MD436327 · TX license P6853 (first issued 2013; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $2,444 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $2,444 |
|---|
| Consulting Fee | $2,444 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. Sep 24, 2025 | Consulting Fee | $1,262 |
| Bayer HealthCare Pharmaceuticals Inc. Nov 19, 2025 | Consulting Fee Vitrakvi · Oncology | $1,182 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $1,084,439 in research payments for these studies, mostly to the institutions running them.
- The LiFFT Study (Lurbinectedin in FET-Fusion Tumors)
Jazz Pharmaceuticals Inc. - Phase 12 study to evaluate palbociclib ibrance in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory solid tumors
Pfizer Inc. - BAY 2731953, A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients withAdvanced Solid or Primary Central Nervous System Tumors
Bayer HealthCare Pharmaceuticals Inc. - Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combin
Novartis Pharmaceuticals Corporation - A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Eli Lilly and Company · Active, not recruiting · NCT03899792 - Phase 1 study to evaluate the safety and pharmacokinetics of palbociclib ibranceregistered in combination with irinotecan and temozolomide and in combination with topotecan and cyclophosphamide in pediatric patients w…
Pfizer Inc. - BAY 2731953, Prospective non-interventional study on TRK fusion cancer patients treated with larotrectinib
Bayer HealthCare Pharmaceuticals Inc. - A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and para…
Novartis Pharmaceuticals Corporation - A Phase I Trial of Cabozantinib (XL184) in Combination With High-dose Ifosfamide in Adults and Children With Relapsed/Refractory Ewing Sarcoma and Osteosarcoma
Exelixis Inc. - Phase II open label global study to evaluate the effect of dabrafenib treatment in children and adolescent subjects with BRAF V600 mutation positive relapsed refractory or progressive HGG tumor
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.